Company Overview

Perimeter Medical Imaging AI, Inc. is a medical technology company operating in the medical imaging, surgical oncology, and artificial intelligence–enabled diagnostics industries. The company develops advanced imaging tools designed to provide surgeons with real-time, high-resolution visualization of tissue microstructure during cancer surgery, with the objective of improving margin assessment and reducing repeat surgeries. Its core focus is breast cancer surgery, a market characterized by high re-excision rates and strong demand for intraoperative decision-support technologies.

The company’s primary product platform is its proprietary Perimeter OCT Imaging System, which combines optical coherence tomography (OCT) with AI-driven image analysis. Perimeter’s strategic positioning centers on delivering real-time, non-destructive imaging at the point of care, differentiating it from traditional pathology workflows that rely on post-operative histological analysis. The company was founded in 2013 and has evolved from an academic research-based venture into a commercial-stage medical device company, progressing through regulatory clearance, clinical validation, and early commercialization in the United States.

Business Operations

Perimeter Medical Imaging AI generates value through the development, regulatory approval, and commercialization of its imaging systems, software, and related consumables. Its operations are organized around a single integrated business model encompassing hardware sales, software-enabled functionality, and service support, with revenue expected to be driven primarily by system placements, recurring disposable components, and future AI software upgrades. The company’s technology platform is built on proprietary OCT hardware and machine-learning algorithms trained on large-scale, annotated surgical imaging datasets.

The company operates primarily in the United States and Canada, with U.S. activities focused on regulatory, clinical, and commercial execution following FDA clearance. Perimeter maintains research and development capabilities in Canada and conducts clinical collaborations with major academic hospitals and cancer centers. Public disclosures indicate no material joint ventures; however, the company has established clinical and research partnerships with healthcare institutions to support data generation and AI model development.

Strategic Position & Investments

Perimeter’s strategic direction emphasizes expanding adoption of intraoperative imaging in breast-conserving surgery and advancing AI-assisted tissue classification to enhance clinical utility. Growth initiatives include increasing commercial penetration in U.S. hospitals, expanding surgeon training programs, and developing next-generation AI-enabled features designed to support real-time margin assessment. The company’s AI roadmap is positioned as a key long-term differentiator, with the potential to shift the product from visualization to decision support.

The company has invested significantly in regulatory approvals, clinical studies, and intellectual property development. It has not disclosed material acquisitions of operating companies; growth has primarily been organic. Strategic investments are concentrated in software development, data infrastructure, and clinical evidence generation to support reimbursement and broader clinical adoption. Data inconclusive based on available public sources regarding material equity investments in external portfolio companies.

Geographic Footprint

Perimeter Medical Imaging AI is headquartered in Toronto, Canada, with a primary operational and commercial presence in the United States, which represents its most significant target market. The company’s U.S. footprint includes regulatory, clinical trial, and commercial sales activities focused on major metropolitan healthcare systems and academic medical centers.

Beyond North America, the company does not currently report material commercial operations in Europe, Asia-Pacific, or other regions. International expansion outside the United States and Canada remains a longer-term objective, contingent on regulatory approvals and commercial scale. Data inconclusive based on available public sources regarding active revenue-generating operations outside North America.

Leadership & Governance

Perimeter Medical Imaging AI is led by an executive team with backgrounds in medical devices, imaging, and healthcare commercialization. The leadership’s stated strategic vision emphasizes clinical evidence, surgeon-centered design, and disciplined commercialization in regulated healthcare markets. Governance is overseen by a board of directors with experience in medtech, capital markets, and healthcare innovation.

Key executives include:

• Jeremy Sobotta – Chief Executive Officer
• Adrian Mendes – Chief Financial Officer
• Dr. Alvaro G. Marquez – Chief Technology Officer
• David Hicks – Vice President, Engineering
• Jon Stevens – Vice President, Sales & Marketing